INFORMATION FOR CENTRES

REGISTER INTEREST

For NHS professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk



Register a participant

To RANDOMISE a participant please call +44 (0)20 7670 4777

Unblind a participant

CONTACT DETAILS

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For NHS professionals

Please log into the members area for Add-Aspirin contact details.

 

PROTOCOL

For a copy of the current protocol please log in to the members area or contact the trial team: mrcctu.add-aspirin@ucl.ac.uk

back to top

CO-ENROLMENT

Aspirin is being given following (or alongside) standard therapy, rather than replacing any part of current treatment. By including individuals who have already taken part in other treatment trials, we will be able to assess how well aspirin works when given in addition to both current and potentially future standard treatments.
Individuals who are participating in the trials below may also enter the Add-Aspirin trial (providing they are otherwise eligible). If you would like to register an individual who has taken part in another trial, which is not listed here, please contact the Add-Aspirin trial team (details above) to discuss this.
More information about the appropriate timing of Add-Aspirin registration relative to other treatments is available in the section below (Timing of trial entry within each cohort)     

Please remember to complete the Co-enrolment CRF for any patients who register in Add-Aspirin and are co-enrolled in one of the below trials, except for those in italic font.                                             

Breast cancer trials                                                                      
FAST-Forward (ISRCTN19906132)
Persephone (ISRCTN52968807)
IMPORT-HIGH (ISRCTN47437448)                                                                                                                                                                            OPPORTUNE (ISRCTN26131497)
EPHOS-B (ISRCTN15004993)                                                                                                                                                                                              RIO
 (ISRCTN92154110)
POSNOC (ISRCTN54765244)
IBIS-II Prevention (ISRCTN37546358)
ARB
PALLET (ISRCTN31243262)
TARGIT-B
STAKT - STAKT patients can enter Add-Aspirin provided they have completed their 30 day post-treatment visit (visit 5).
ROSCO (ISRCTN00430739)
POETIC-2 Feasibility
Chemo-NEAR
Bridging the Age Gap
POBRAD-M
CAVA
PROSPER
HORIZONS
EFFECT

Bowel cancer trials
FOxTROT (ISRCTN87163246)
ARISTOTLE (ISRCTN9351447)
HART (ISRCTN25616490)
MERCURY 2
FOCCUS
SERENADE
CAVA
NeoART
VERDDICT
PRISM
PREVENTT

Stomach/oesophageal cancer trials
ST03 (ISRCTN46020948)
ROMIO (ISRCTN59036820)
STAT-ROC (ISRCTN00131824)
CAVA
BOSS

  • Prostate cancer trials
    DELINEATE
    RADICALS-RT (ISRCTN40814031)- RADICALS-RT patients randomised into either arm of the trial (immediate or salvage post-operative radiotherapy) should only register in Add-Aspirin once radiotherapy is complete.

    UKGPCS
    VoxTox
    CAVA
    ProSpare II
    Clarity-Pro

back to top

  

TIMING OF TRIAL ENTRY FOR EACH COHORT

Please click on the relevant cohort to view treatment pathway diagrams

BREAST   COLORECTAL   GASTRO   PROSTATE

 

back to top


SAMPLE COLLECTION

All participants that are registered in Add-Aspirin will be asked if they consent to donate a blood sample and a tumour sample for future cancer research. Samples should be sent to your centre’s allocated bio-bank. Please refer to the Add-Aspirin Translational Manual and Biobank addresses available in the members area for more information on what to send.

back to top
 

TRAINING  

Add-Aspirin Initiation slides and MDT slides are available in the members' area of the Add Aspirin website. Please contact us for more details: mrcctu.add-aspirin@ucl.ac.uk

back to top



The trial is being jointly funded by Cancer Research UK (grant number C471 /A15015, www.cancerresearchuk.org), the National Institute for Health Research Health Technology Assessment Programme (project number 12/01/38, www.nihr.ac.uk) and the MRC Clinical Trials Unit at UCL.
© Add-Aspirin, MRC CTU at UCL cookies